Advertisement
Screener

Century Therapeutics, Inc. (IPSC) Price / Book

2.8 / 5 stars · 68/120 Roast Me

Century Therapeutics, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

  • Century Therapeutics, Inc. price/book ratio for the quarter ending 2026-06-30 was 1.9, a 729.41% increase year-over-year.
  • Century Therapeutics, Inc. price/book ratio for the quarter ending 2026-03-31 was 1.54, a 801.50% increase year-over-year.
  • Century Therapeutics, Inc. price/book ratio for the quarter ending 2025-12-31 was 0.54, a 0.07% increase year-over-year.
  • Century Therapeutics, Inc. price/book ratio for the quarter ending 2025-09-30 was 0.24, a 66.93% decline year-over-year.
  • Century Therapeutics, Inc. price/book ratio for fiscal 2026 was 1.9.
  • Century Therapeutics, Inc. price/book ratio for fiscal 2025 was 0.54, a 0.07% increase from fiscal 2024.
  • Century Therapeutics, Inc. price/book ratio for fiscal 2024 was 0.54, a 50.45% decline from fiscal 2023.
  • Century Therapeutics, Inc. price/book ratio for fiscal 2023 was 1.08, a 16.32% increase from fiscal 2022.
Available history
2021-06-30 to 2026-06-30
Data captured

Historical Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-301.9$441.44M$232.35M
2026-03-311.54$407.03M$264.74M
2025-12-310.54$85.45M$158.94M
2025-09-300.24$43.09M$176.35M
2025-06-300.23$48.08M$209.9M
2025-03-310.17$41.01M$240.44M
2024-12-310.54$86.69M$161.36M
2024-09-300.74$144.58M$195.69M
2024-06-300.97$215.61M$222.1M
2024-03-311.42$252.2M$177.88M
2023-12-311.08$200.31M$184.75M
2023-09-300.54$119.03M$219.23M
2023-06-300.76$187.42M$247.57M
2023-03-310.74$205.1M$277.18M
2022-12-310.93$282.18M$302.74M
2022-09-301.74$575.45M$330.21M
2022-06-301.35$483.72M$357.95M
2022-03-311.88$725.01M$386.66M
2021-12-312.34$927.39M$396.24M
2021-09-303.25$1.37B$422.99M
2021-06-303.57$1.6B$447.6M

Annual Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-301.9$441.44M$232.35M
2025-12-310.54$85.45M$158.94M
2024-12-310.54$86.69M$161.36M
2023-12-311.08$200.31M$184.75M
2022-12-310.93$282.18M$302.74M
2021-12-312.34$927.39M$396.24M

Similar stocks

Stock NameCountryMarket CapPE Ratio
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Ocugen, Inc. (OCGN)United States$0.343B-6.34
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05